Company intelligence / Profile preview

NovaResp Technologies

Halifax, Nova Scotia, Canadanovaresp.ai ↗

Ownership: Private
Employees: ~24
Development stage: Preclinical

Overview

Pre-market clinical studies are underway to evaluate the comfort and adherence benefits of cMAP® software integrated with CPAP machines in patients diagnosed with obstructive sleep apnea. Results will support regulatory submissions and commercialization efforts. No published pivotal trial results or commercial launch as of June 2025.

Therapeutic areas: Pulmonology
Modalities: DeviceSoftware (AI-enabled platform)Non-pharmacological therapy (CPAP adjunct)
Industry: Therapeutic Medical Devices

Partnerships

CAN Health NetworkNova Scotia Innovation Hub

Beyond the preview

Go deeper on NovaResp Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NovaResp Technologies.

Explore the full profile